

Toleranzia receives funding from Vinnova for ANCA vasculitis project

Toleranzia AB ("Toleranzia" or the "Company") announces today that the Company has been awarded a grant from Vinnova for a project aimed at developing a new unique disease-specific treatment for ANCA vasculitis. The project is awarded a total of SEK 2.9 million, which will be distributed among several grant recipients, of which Toleranzia is awarded SEK 1.7 million.

The grant is awarded by Vinnova with financial support from Medtech4Heath and Swelife within the framework of the call "Swelife and Medtech4Health - Collaborative project for better health in the fall of 2022". Toleranzia will run the project together with Lund University's Kidney Research Lab, Region Skåne and SciCross AB. The project runs for two years starting from April 3, 2023.

- We are extremely pleased to have been awarded a grant from Vinnova for the continued development of our drug candidate TOL3 as a new, disease-specific and effective treatment for the autoimmune blood vessel disease ANCA vasculitis. TOL3, like our other drug projects, is based on the Company's tolerance technology, which has great potential for the development of new drugs in autoimmune diseases," comments Charlotte Fribert, CEO of Toleranzia.

For further information, please contact

Charlotte Fribert - CEO, Toleranzia AB

Tel: +46 763 19 98 98

Email: charlotte.fribert@toleranzia.com

About Medtech4Heath

Medtech4Health strive to increase the number and quality of new innovative products and services within medtech. In collaboration with patients, healthcare, academia, and business, we contribute to increasing value for people affected by disease in their everyday lives.

Medtech4Health is funded by the Swedish government through the Swedish innovation authority Vinnova, Swedish Energy Agency and Swedish Research Council for Sustainable Development Formas, and by the programme's partners.

www.medtech4health.se

About Swelife

Swelife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation authority Vinnova, Swedish Energy Agency and Swedish Research Council for Sustainable Development Formas, and by the programme's partners, and by the programme's partners. We support collaboration within academia, industry, and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.

www.swelife.se

About Toleranzia AB (publ)

Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.

Attachments

[Toleranzia receives funding from Vinnova for ANCA vasculitis project](#)